In this selection, we summarize for you the most important scientific news of 2020 in the field of pharmacology.
01- Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness
Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to the COLCOT trial, originally presented at the American Heart Association (AHA) 2019 Scientific Session and simultaneously published in the New England Journal of Medicine (NEJM). The new information featured at the virtual ACC 2020 refers to its cost-effectiveness.
Read also HERE
02- ESC 2020 | Ticagrelor Might Increase Bleeding and Mortality in the Elderly
Ticagrelor compared against clopidogrel produces more bleeding and also more deaths in patients over 80 recently undergoing acute myocardial infarction.
Read also HERE
03- ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality
Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in patients with heart failure, even in those without diabetes.
Read also HERE
04- ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events
Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization.
Read also HERE
05- TCT 2020 | Ticagrelor Monotherapy After ST-Segment Elevation Infarction
Ticagrelor monotherapy after 3 months of dual antiplatelet therapy in patients who experienced ST-segment elevation infarction significantly reduces major bleeding without increasing ischemic risk.
Read also HERE
06- AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients
High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural events and instead see increased costs and minor bleeding rate.
Read also HERE
07- AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure
Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction.
Read also HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology